JP2004516295A - サブタイプ選択的なｎ−メチル−ｄ−アスパラギン酸拮抗薬としてのピペリジン誘導体 - Google Patents

サブタイプ選択的なｎ−メチル−ｄ−アスパラギン酸拮抗薬としてのピペリジン誘導体 Download PDF

Info

Publication number
JP2004516295A
JP2004516295A JP2002551566A JP2002551566A JP2004516295A JP 2004516295 A JP2004516295 A JP 2004516295A JP 2002551566 A JP2002551566 A JP 2002551566A JP 2002551566 A JP2002551566 A JP 2002551566A JP 2004516295 A JP2004516295 A JP 2004516295A
Authority
JP
Japan
Prior art keywords
ylmethyl
benzoxazol
piperidin
dihydroisoxazol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2002551566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516295A5 (https=
Inventor
ブライアン・エドワード・コーンバーグ
ラッセル・アンドルー・リュースウェイト
デイヴィッド・ダグラス・マニング
シャム・シュリドハール・ニーカム
イーアン・レズリー・スコット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2004516295A publication Critical patent/JP2004516295A/ja
Publication of JP2004516295A5 publication Critical patent/JP2004516295A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002551566A 2000-12-21 2001-11-30 サブタイプ選択的なｎ−メチル−ｄ−アスパラギン酸拮抗薬としてのピペリジン誘導体 Abandoned JP2004516295A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25783200P 2000-12-21 2000-12-21
PCT/IB2001/002277 WO2002050070A2 (en) 2000-12-21 2001-11-30 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists

Publications (2)

Publication Number Publication Date
JP2004516295A true JP2004516295A (ja) 2004-06-03
JP2004516295A5 JP2004516295A5 (https=) 2005-06-23

Family

ID=22977943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002551566A Abandoned JP2004516295A (ja) 2000-12-21 2001-11-30 サブタイプ選択的なｎ−メチル−ｄ−アスパラギン酸拮抗薬としてのピペリジン誘導体

Country Status (13)

Country Link
US (1) US6642256B2 (https=)
EP (1) EP1345935A2 (https=)
JP (1) JP2004516295A (https=)
AU (1) AU2002223968A1 (https=)
BR (1) BR0116311A (https=)
CA (1) CA2436699A1 (https=)
HN (1) HN2001000280A (https=)
MX (1) MXPA03004652A (https=)
PA (1) PA8535901A1 (https=)
PE (1) PE20020882A1 (https=)
TN (1) TNSN01175A1 (https=)
UY (1) UY27081A1 (https=)
WO (1) WO2002050070A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006137465A1 (ja) * 2005-06-24 2006-12-28 Shionogi & Co., Ltd. 含窒素複素環誘導体
JP2008530120A (ja) * 2005-02-10 2008-08-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 選択的な５ｈｔ２ａアンタゴニストとしての置換されたビスアリールおよびヘテロアリール化合物
JP2011215433A (ja) * 2010-03-31 2011-10-27 Jsr Corp 感放射線性樹脂組成物、重合体及び化合物
JP2015107980A (ja) * 2010-06-11 2015-06-11 ローズ テクノロジーズ Ｎ−アリル化合物の調製のための遷移金属触媒プロセスおよびその使用
JP2020510007A (ja) * 2017-03-12 2020-04-02 ワン，シャオドン オピオイド受容体調節因子としての多環式アミン

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) * 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
JP2007504123A (ja) 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害剤
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
DK2124944T3 (da) 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
CA3033827A1 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists
CN117466836B (zh) * 2023-11-14 2026-02-06 万华化学集团股份有限公司 一种合成烯丙基叔胺的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4368996A (en) 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
DE19531321A1 (de) 1995-08-25 1997-02-27 Merck Patent Gmbh Piperidinylmethyloxazolidinone
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
DE19739332C1 (de) 1997-09-09 1998-11-26 Merck Patent Gmbh Piperidinylmethyloxazolidinon-Derivat
US6015824A (en) 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
WO2000018763A2 (en) 1998-09-29 2000-04-06 Neurogen Corporation 2-(2,3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530120A (ja) * 2005-02-10 2008-08-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 選択的な５ｈｔ２ａアンタゴニストとしての置換されたビスアリールおよびヘテロアリール化合物
WO2006137465A1 (ja) * 2005-06-24 2006-12-28 Shionogi & Co., Ltd. 含窒素複素環誘導体
JP2011215433A (ja) * 2010-03-31 2011-10-27 Jsr Corp 感放射線性樹脂組成物、重合体及び化合物
JP2015107980A (ja) * 2010-06-11 2015-06-11 ローズ テクノロジーズ Ｎ−アリル化合物の調製のための遷移金属触媒プロセスおよびその使用
US9624232B2 (en) 2010-06-11 2017-04-18 Rhodes Technologies Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof
US9657030B2 (en) 2010-06-11 2017-05-23 Rhodes Technologies Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof
JP2020510007A (ja) * 2017-03-12 2020-04-02 ワン，シャオドン オピオイド受容体調節因子としての多環式アミン
JP7376358B2 (ja) 2017-03-12 2023-11-08 ワン，シャオドン オピオイド受容体調節因子としての多環式アミン

Also Published As

Publication number Publication date
WO2002050070A3 (en) 2002-09-19
TNSN01175A1 (fr) 2005-11-10
CA2436699A1 (en) 2002-06-27
HN2001000280A (es) 2002-01-30
PE20020882A1 (es) 2002-09-28
WO2002050070A2 (en) 2002-06-27
PA8535901A1 (es) 2002-08-29
US20030018021A1 (en) 2003-01-23
MXPA03004652A (es) 2003-09-05
AU2002223968A1 (en) 2002-07-01
EP1345935A2 (en) 2003-09-24
BR0116311A (pt) 2003-09-23
US6642256B2 (en) 2003-11-04
UY27081A1 (es) 2002-07-31

Similar Documents

Publication Publication Date Title
US6642256B2 (en) Piperidine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
AU722883B2 (en) Cyclopentyl tachykinin receptor antagonists
US5750549A (en) Cycloalkyl tachykinin receptor antagonists
AU2017263361B2 (en) Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors
DE69706658T2 (de) Substituierte 4-hydroxyphenylalkansaure-derivate mit agonistischer wirkung auf ppar-gamma
AU2003284984B2 (en) Gamma-aminoamide modulators of chemokine receptor activity
ES2248840T3 (es) Antagonistas de vasopresina v1a no peptidilicos.
EP3921038A1 (en) Il-17a modulators and uses thereof
HK1225717A1 (zh) β-内酰胺後叶加压素V1A拮抗剂
CA2615813C (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
US6828341B2 (en) Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
DE69903319T2 (de) Fkbp inhibitoren
WO2007109098A2 (en) HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS
CN109476653A (zh) 类视黄醇相关孤儿受体γ的杂芳族调节剂
CN106459031A (zh) 作为磷酸二酯酶4(pde4)的酶抑制剂和毒蕈碱m3受体拮抗剂的氨基甲酸酯衍生物
CA2924022A1 (en) 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines
BR112021014539A2 (pt) Composto, ativador sirt6, composição farmacêutica, método para tratar e/ou prevenir uma doença inflamatória periférica e uso do composto
WO1998017660A1 (en) Phenyl spiroethercycloalkyl tachykinin receptor antagonists
US20110003780A1 (en) Hydrogen chloride salt of a substituted 5-oxazol-2-yl-quinoline compound and a process for the production thereof
CA2234913A1 (en) Cyclopentyl tachykinin receptor antagonists
CA3039586A1 (en) 4,4a,5,7-tetrahydro-3h-furo[3,4-b]pyridinyl compounds
HK1076814B (en) β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS
HK1189228A (en) β-LACTAMYL VASOPRESSIN V1AANTAGONISTS

Legal Events

Date Code Title Description
A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20070228